<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-30 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-30</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-30</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-1.html">extraction-schema-1</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <p><strong>Paper ID:</strong> paper-24891999</p>
                <p><strong>Paper Title:</strong> Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study</p>
                <p><strong>Paper Abstract:</strong> Epidermal growth factor receptor ( EGFR ) is one of the targeted molecular markers in many cancers including lung malignancies. Gefitinib and erlotinib are two available therapeutics that act as specific inhibitors of tyrosine kinase (TK) domains. We performed a case-control study with formalin-fixed paraffin-embedded tissue blocks (FFPE) from tissue biopsies of 167 non-small cell lung carcinoma (NSCLC) patients and 167 healthy controls. The tissue biopsies were studied for mutations in exons 18-21 of the EGFR gene. This study was performed using PCR followed by DNA sequencing. We identified 63 mutations in 33 men and 30 women. Mutations were detected in exon 19 (delE746-A750, delE746-T751, delL747-E749, delL747-P753, delL747-T751) in 32 patients, exon 20 (S786I, T790M) in 16, and exon 21 (L858R) in 15. No mutations were observed in exon 18. The 63 patients with EFGR mutations were considered for upfront therapy with oral tyrosine kinase inhibitor (TKI) drugs and have responded well to therapy over the last 15 months. The control patients had no mutations in any of the exons studied. The advent of EGFR TKI therapy has provided a powerful new treatment modality for patients diagnosed with NSCLC. The study emphasizes the frequency of EGFR mutations in NSCLC patients and its role as an important predictive marker for response to oral TKI in the south Indian population.</p>
                <p><strong>Cost:</strong> 0.013</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e30.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e30.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>South Indian (Hyderabad) NSCLC study</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Hospital-based NSCLC patient cohort from Hyderabad, South India (this study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Prospective case-control study of EGFR exon 18-21 mutations by PCR and Sanger sequencing in 167 NSCLC patients and 167 controls from Hyderabad, India; reports mutation frequencies, exon distribution, and associations with gender and smoking.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>167 NSCLC patients (cases) and 167 matched healthy controls; all subjects natives of Hyderabad, Telangana, South India. Cases: 112 males, 55 females; mean age 55.1 years. Stage distribution: majority stage IV.</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>South Indian (Indian)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>63/167 = 37.7% of NSCLC patients harbored an EGFR mutation (exons 18-21).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Exon 19 deletions (del E746-A750, del E746-T751, del L747-E749, del L747-P753, del L747-T751) in 32 patients (19.1% of cohort); Exon 20 mutations (including T790M, S786I) in 16 patients (9.6%); Exon 21 L858R in 15 patients (9%); No exon 18 (G719) mutations detected.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Cohort smokers: 90/167 (53.9%); non-smokers: 77/167 (46.1%).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Among the 63 EGFR-mutant patients, 50 were smokers and 13 were non-smokers (i.e., a majority of EGFR-mutant cases in this cohort were smokers), which the authors note is contrary to many prior reports.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>General lung-cancer environmental factors are listed (tobacco smoke, radon, arsenic, cadmium, chromates, asbestos) but no cohort-specific exposure measurements reported.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>The paper discusses previously reported germline/polymorphic variants associated with EGFR biology (e.g. -216G/T, D994D, EGFR intron 1 CA-SSR length and CA-19 genotype, EGFR 8227G/A) and other cancer-related polymorphisms cited in the literature, but no germline genotyping was performed in this cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>No internal multi-ancestry comparison in this study cohort. The paper compares its observed frequency (37.7%) with previously reported frequencies from other regions in the discussion.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors discuss several proposed mechanisms from the literature: germline EGFR polymorphisms (e.g. -216G/T, CA-SSR) may predispose to somatic EGFR mutations (especially exon 19 microdeletions); CA repeat length may affect EGFR expression; age-related accumulation of mutations; and gene-environment interactions, but no mechanistic experiments were performed in this study.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>All cases were NSCLC; EGFR-mutant patients showed better response to EGFR-TKI therapy overall (majority treated with TKIs), with exon 19 deletions and L858R associated with response; exon 20 mutations (including T790M) associated with resistance in some patients.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Authors note potential biases: small sample size, clinically selected patients (molecular testing often ordered after clinicopathologic review), and confounding of smoking status by age and sex.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>This cohort represents urban South India (Hyderabad); authors contrast their finding with international reports (see separate entries).</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e30.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e30.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>East Asian populations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>East Asian populations (aggregated literature reports cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Literature-cited aggregate that EGFR mutation prevalence in East Asian NSCLC patients is higher than in Western populations (reported around ~30% in this paper). Associated with female sex, non-smoking status, and adenocarcinoma histology in many studies.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not an original cohort in this paper; represents aggregated literature reports of East Asian NSCLC patients (examples in cited studies from China, Korea, Taiwan, Japan).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>East Asian (Chinese, Korean, Japanese, Taiwanese etc., as referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported in this paper as about ~30% in East Asian patients (literature aggregate).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Paper cites that deletions in exon 19 and L858R in exon 21 occur most frequently in many series of East Asian patients (consistent with the study's exon 19 and L858R predominance).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Literature-cited pattern: EGFR mutations are often more frequent in never-smokers and in females in East Asian series (the paper cites multiple Asian studies showing that pattern).</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Typically reported in cited Asian studies as 'more common in non-smokers' (though the present Indian cohort differed).</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>The paper does not report specific East-Asian environmental exposure measurements, but lists general lung carcinogens (tobacco, radon, metals, asbestos) as possible contributors to population differences.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Paper references studies linking germline EGFR polymorphisms (e.g. intron 1 CA-SSR, -216G/T, EGFR 8227G/A) and other loci (e.g. CHRNA3) to lung cancer susceptibility or to somatic EGFR mutation patterns in East Asian populations.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Cited comparisons in the discussion contrast East Asian ~30% vs lower frequencies in Western populations (10-15%) and African-Americans (19%).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Hypothesized mechanisms discussed include higher prevalence of germline variants that predispose to somatic EGFR mutations, differences in smoking prevalence and patterns, gene-environment interactions, and demographic factors such as age and sex distributions.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Cited pattern: EGFR-mutant tumors in East Asians are often adenocarcinomas, in females, and in never-smokers (per multiple cited Asian series).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Authors note that cross-study differences can arise from sample selection, small cohorts, histology mix, and differing testing strategies.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Paper cites studies from multiple East Asian locales (Taiwan, Korea, China, Japan) indicating broadly higher frequencies in East Asia compared with Western populations.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e30.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e30.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>North American/European populations</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>North American and European populations (aggregated literature reports cited in paper)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Literature-cited aggregate indicating lower EGFR mutation prevalence in NSCLC patients from North America and Europe compared with East Asians (~10-15% reported here).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Aggregated reports from North American and European NSCLC series as cited in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>North American/European (Caucasian/European ancestry)</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported in this paper as approximately 10-15% in North American and European patients (literature-cited range).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Deletions in exon 19 and L858R in exon 21 are also common types when mutations occur, though overall prevalence is lower than in East Asians.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Cited literature generally reports more EGFR mutations among never-smokers and females, but the paper does not provide cohort-level smoking breakdown for Western populations.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>In general literature cited, EGFR mutations are more frequent among never-smokers compared with smokers in Western cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Paper lists common lung carcinogens (tobacco etc.) but does not provide Western-specific exposure data.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Paper discusses possible role of germline polymorphisms but does not provide Western-population-specific germline findings.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Compared qualitatively to East Asians (~30%) and African-Americans (19%) in the discussion.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Possible explanations include lower prevalence of predisposing germline variants, different smoking patterns and demographic structures, and study selection biases.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Not detailed in this paper beyond general literature patterns (EGFR-mutant tumors often adenocarcinoma and in never-smokers).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Cross-study differences may derive from selection bias, histologic composition, and differing testing methods.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Paper reports aggregate Western prevalence but no within-region stratification.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e30.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e30.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>African-American population</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>African-American NSCLC patients (literature-cited frequency)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Paper cites a prior study reporting EGFR mutation frequency in African-American lung adenocarcinoma patients (reported here as 19%).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Not studied directly in this paper; frequency cited from the literature (Reinersman et al. and others).</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>African-American</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported in this paper as about 19% (literature-cited).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Not specified in detail within this paper for African-Americans, but the general common activating mutations (exon 19 deletions and exon 21 L858R) are referenced as dominant types overall.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>No African-Americanâ€“specific smoking breakdown provided in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Not specified for this group in the paper.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No group-specific environmental exposures discussed for African-Americans in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Paper does not provide specific germline variant data for African-Americans; germline mechanisms discussed are generalized.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Mentioned for comparison with East Asian (~30%) and Western (10-15%) frequencies.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Not specifically proposed for African-Americans beyond general hypotheses (genetic background, exposures, demographics).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Not detailed in this paper.</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Paper does not detail confounders specific to African-American studies but acknowledges cross-study differences may reflect selection/testing biases.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>Paper provides a single literature-cited prevalence estimate rather than within-region breakdowns.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e30.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e30.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in lung cancer across different ethnic or ancestral populations, particularly comparing East Asian patients to other populations, including environmental factors, genetic background, and proposed mechanisms for population differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Indian (previous reports)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Prior Indian NSCLC EGFR mutation reports (literature-cited)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites prior reports from India giving EGFR mutation rates around 35%, roughly consistent with this study's 37.7%.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Previous Indian cohorts (not part of this study) summarized in discussion; specific prior report cited with ~35% mutation rate.</td>
                        </tr>
                        <tr>
                            <td><strong>population_ancestry</strong></td>
                            <td>Indian</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>Reported from prior literature in this paper as ~35% (comparable to 37.7% observed in the Hyderabad cohort).</td>
                        </tr>
                        <tr>
                            <td><strong>specific_egfr_mutations</strong></td>
                            <td>Prior Indian reports similarly note predominance of exon 19 deletions and exon 21 L858R, with low exon 18 mutation rates in some series.</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status</strong></td>
                            <td>Some prior Indian series reported higher mutation frequency in non-smokers and females, but the present study differs; details vary across reports.</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_smoking_association</strong></td>
                            <td>Prior Indian studies often align with global pattern (more frequent in non-smokers), but mixed results exist; this paper highlights contradictions across Indian data.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>No India-specific environmental exposure quantification provided in this paper beyond general carcinogens.</td>
                        </tr>
                        <tr>
                            <td><strong>germline_genetic_factors</strong></td>
                            <td>Paper references general literature on germline polymorphisms (EGFR CA-SSR, -216G/T) but no India-specific germline data.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td>Paper compares its observed Indian frequency (~37.7%) with previously reported Indian (~35%) and global frequencies (East Asian ~30%, Western 10-15%).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Authors suggest differences may arise from sample selection, genetics, and environmental/demographic factors but do not present direct mechanistic data.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_characteristics</strong></td>
                            <td>Similar mutation spectrum to other series (exon 19 deletions and L858R predominant).</td>
                        </tr>
                        <tr>
                            <td><strong>confounding_factors</strong></td>
                            <td>Authors caution that small sample sizes and clinical selection may overestimate mutation prevalence in Indian series.</td>
                        </tr>
                        <tr>
                            <td><strong>geographic_variation</strong></td>
                            <td>This paper is from Hyderabad (South India); it and prior Indian reports indicate mutation rates in India are closer to East Asian levels than to Western levels in some series.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy <em>(Rating: 2)</em></li>
                <li>Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans <em>(Rating: 2)</em></li>
                <li>EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy <em>(Rating: 2)</em></li>
                <li>Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population <em>(Rating: 2)</em></li>
                <li>Screening for epidermal growth factor receptor mutations in lung cancer <em>(Rating: 2)</em></li>
                <li>Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers <em>(Rating: 2)</em></li>
                <li>High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features <em>(Rating: 1)</em></li>
                <li>Association of an EGFR intron 1 SNP with never smoking female lung adenocarcinoma patients <em>(Rating: 1)</em></li>
                <li>Functional EGFR germ line polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>